Thymogen (EW) — Khavinson Peptide Research Archive

Registered Russian immune drug (Glu-Trp dipeptide, immunopharmacologically active fragment of thymosin family work).

Extract counterpart: Thymogen is itself an older registered RU immune drug (Glu-Trp). Same organ lineage as Thymalin.

Extract vs synthetic gap: the human outcome data (including the 266-patient mortality cohort) was collected on extracts; vendors sell synthetic fragments. No head-to-head trial exists — evidence does not transfer between them. Details →

Khavinson studies (6 matched, 1992–2001)

Keyword-filtered from the 472-publication database (khavinson.info). EXTRACT/SYNTHETIC tags are title-text heuristics — verification is on the reader. Full tag legend: evidence-tiers.html

[157] Grigoriev E.I., Kotchnev I.N., Kudriavtseva T.A., Grigoriev A.E., Khavinson V.Kh. New peptide immunomodulators Vilon and Thymogen. Chemical and biophysical aspects of their action in the water medium. // 26 th European Peptide Symposium. - Montpellier, France. - Proc.: EDK. - 2001. - P. 475-476. (2001)syn

[161] Maksimov I.B., Moshetova L.K., Khavinson V.Kh., Zozulya T.A., Kolesnikov D.O. Correction of delayed corneal epithelization after photorefractive Keratectomy (PRK) with thymogen. // 17 th annual NIDEK International Excimer Laser Symposium. - Monaco. - Abstr. - 2001. - P. 27-28. (2001)untag

[171] Grigoriev E., Kotchnev I., Kudriavtseva T., Grigoriev A., Khavinson V. New peptide immunomodulators vilon and thymogen, chemical and biophysical aspects of their action in the water medium. // J. of Peptide Science. - 2000. - Vol. 6. Suppl. - P. 139. (2000)syn

[192] Anisimov V.N., Khavinson V.Kh., Morozov V.G. Effect of synthetic dipeptide Thymogen® (Glu-Trp) on life span and spontaneous tumor incidence in rats. // The Gerontologist. - 1998. - Vol. 38, Special issue 1. - P. 7 - 8. (1998)syn

[194] Anisimov V.N., Khavinson V.Kh., Morozov V.G., Pavelyeva I.A., Petrov N.N. Effect of synthetic dipeptide thymogen (Glu-Trp) on 90Sr-137Cs-induced carcinogenesis in rats. // Abstr. of XV European Association for Cancer Research. - Stockholm. - 1998. - P. 158. (1998)syn

[224] Morozov V.G., Khavinson V.Kh. Immunogeroprotective effects of the synthetic thymic peptide - Thymogen. // 1st International Conference on immunorehabilitation “Rehabilitation of immune system”. - Abstr. - 1992. -P. 51. (1992)syn

Independent (non-Khavinson) studies

Thymosin alpha-1 (adjacent class) — TESTS trial, BMJ 2025, Phase 3, n=1106, sepsis mortality independent

Result: NULL. 23.4% vs 24.1% 28-day mortality, HR 0.99.

Significance: Largest properly blinded trial of any thymic peptide. Effect seen in smaller trials evaporated at scale. Cautionary parallel for Thymalin claims.

Reddit meta-scrape

1 post (r/1vxai3x, Thymogen Alpha-1 capsules for ME/CFS) + 1 comment.

Neutral / no-effect

Question posted, minimal response. One commenter: 'Oral TA-1 would just be ridiculously expensive dietary protein. It would get digested.'

MEASURED vs VIBE: 0/0.

Common protocol: Injectable Thymogen: 100mcg SQ x 10-day blocks.

Key takeaway: Minimal Reddit presence. Oral form questioned by community as impractical (digestion destroys peptide).

Measurement protocol — concrete testable endpoints

Same immune panel as Thymalin (CD3/CD4/CD8, NK activity, IL-2, TREC), 8–12 weeks pre/post.

All endpoints on one page: measurement-protocols.html · Evidence-tier legend: evidence-tiers.html